Tylenol Delivers J&J Relief As Global 'Consumer Staples' Sales Slump
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
J&J says Tylenol outpaced other analgesics in the first quarter as its OTC franchise grew 1.4% on a reported basis to $1.01 bn. CFO Dominic Caruso said new consumer products will add 2 points of incremental growth to the segment in 2017.
You may also be interested in...
J&J Promotes Preventive Care, Wellness In US Health Debate
OTC makers' stakes include loosening rules on paying for consumer products with pre-tax savings and encouragement of self-care to maintain wellness.
Colgate Builds On Oral Care, Counts E-commerce As Emerging Sector
Colgate's oral care business gains market share in the third quarter on new product sales, including Colgate Total Daily Repair and Colgate Optic White High Impact. President and CEO Ian Cook says the firm is not underrepresented in e-commerce and it will build its online sales “thoughtfully.”
P&G Keeps Direct-to-Consumer In Perspective, Retail Distribution Primary
Procter & Gamble remains focused on conventional retail sales, though it will continue to leverage the DTC distribution channel for several categories, CFO Jon Moeller says. Health care sales in the firm's latest quarter jumped 7%, outperforming other sectors.